Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis.

Rey-Ares L, Ciapponi A, Pichon-Riviere A.

Arch Argent Pediatr. 2012 Dec;110(6):483-9. doi: 10.1590/S0325-00752012000600005. Review. English, Spanish.

2.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

PMID:
19586656
3.

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.

Lu B, Kumar A, Castellsagué X, Giuliano AR.

BMC Infect Dis. 2011 Jan 12;11:13. doi: 10.1186/1471-2334-11-13. Review.

5.

Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.

Mandic A.

J BUON. 2012 Jul-Sep;17(3):422-7. Review.

PMID:
23033276
6.

HPV catch-up vaccination of young women: a systematic review and meta-analysis.

Couto E, Sæterdal I, Juvet LK, Klemp M.

BMC Public Health. 2014 Aug 23;14:867. doi: 10.1186/1471-2458-14-867.

7.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

8.

HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W.

Vaccine. 2007 Dec 5;25(50):8352-8. Epub 2007 Sep 29. Review.

PMID:
17996990
9.

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Rambout L, Hopkins L, Hutton B, Fergusson D.

CMAJ. 2007 Aug 28;177(5):469-79. Epub 2007 Aug 1. Review.

10.

Efficacy of human papillomavirus vaccines: a systematic quantitative review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR.

Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100. Review.

PMID:
19823051
11.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
12.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075170
13.

Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.

Hariri S, Johnson ML, Bennett NM, Bauer HM, Park IU, Schafer S, Niccolai LM, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Cancer. 2015 Aug 15;121(16):2775-81. doi: 10.1002/cncr.29266. Epub 2015 Jun 22.

14.

Introducing human papillomavirus vaccines - questions remain.

Paavonen J, Lehtinen M.

Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Review.

PMID:
18382882
15.

Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.

Harper DM.

Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi: 10.1016/j.ygyno.2008.06.029. Epub 2008 Jul 22.

PMID:
18649932
16.

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ.

Int J Cancer. 2015 Oct 15;137(8):1931-7. doi: 10.1002/ijc.29508. Epub 2015 Jun 3.

17.

Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?

Tomljenovic L, Spinosa JP, Shaw CA.

Curr Pharm Des. 2013;19(8):1466-87. Review.

PMID:
23016780
18.

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW, Abdullah N, Levine D, Johnson ML, Steinau M, Markowitz LE; HPV-IMPACT Working Group.

Vaccine. 2015 Mar 24;33(13):1608-13. doi: 10.1016/j.vaccine.2015.01.084. Epub 2015 Feb 11.

PMID:
25681664
19.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

20.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group.

Lancet. 2006 Apr 15;367(9518):1247-55.

Supplemental Content

Support Center